Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03080116
Other study ID # S58827
Secondary ID 2016-002854-19
Status Recruiting
Phase Phase 2
First received
Last updated
Start date March 28, 2019
Est. completion date December 30, 2021

Study information

Verified date December 2020
Source Universitaire Ziekenhuizen Leuven
Contact Steven Joniau, MD PhD
Phone +32 16 34 66 87
Email steven.joniau@uzleuven.be
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

RATIONALE: Neoadjuvant hormonal therapy using luteinizing hormone releasing hormone (LHRH) agonists and/or anti-androgens has already demonstrated to downstage primary prostate cancer in patients treated by radical prostatectomy without a survival benefit. There is no evidence yet of a survival impact of LHRH antagonist (LHRHa) +/- new-generation anti-androgens in this setting. Thus novel studies are needed to assess this treatment combination. PURPOSE: To assess the difference in treatment antitumor effect between arms by measuring pathological tumor volume with minimal residual disease (MRD) following radical prostatectomy + pelvic lymph-node dissection (RP + PLND) for intermediate or high-risk prostate cancer patients.


Description:

PRIMARY OBJECTIVE: To assess the difference in antitumor effect between the treatment arms by measuring MRD following radical prostatectomy. SECONDARY OBJECTIVES: To measure differences between study arms in - Proportions of post neoadjuvant prostate specific antigen (PSA) ≤ 0.3 ng/ml as a predictor of prostate cancer mortality - T down-staging, complete pathological response, PSA kinetics, Testosterone kinetics, operation time, blood loss, grade of surgical difficulty - New generation hybrid imaging 68Ga PSMA (Prostate-Specific Membrane Antigen) PET/MR (Positron emission tomography/Magnetic Resonance) derived parameters - Early biochemical recurrence as prognostic factor of prostate cancer mortality - Transcriptome and genome - Tissue microarrays (TMA) protein expression (DNA repair, resistance etc.) by immunohistochemistry - Perioperative safety and tolerability - Quality of life, erection recovery, continence through validated preoperative and postoperative questionnaires pre and postop (IEEF5, ICIQ, EORTC QLQ-C30) OUTLINE: interventional, single center, phase II, randomized, double blind, placebo controlled trial.


Recruitment information / eligibility

Status Recruiting
Enrollment 84
Est. completion date December 30, 2021
Est. primary completion date June 30, 2021
Accepts healthy volunteers No
Gender Male
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: 1. Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial 2. Before patient registration/randomization, written informed consent must be given according to ICH/GCP, and national/local regulations 3. Male aged 18 years or older (within 80 years) 4. Histologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation or small cell features 5. Diagnosis of intermediate (at least 2 of the following factors: cT2b, biopsy GS 7, PSA 10-20ng/ml) or high-risk prostatic adenocarcinoma (clinical stage=T2c and/or biopsy GS=8 and/or PSA>20ng/ml), cN0-cN1, cM0. 6. Patient amenable for open or robotic radical prostatectomy + pelvic lymph node dissection 7. ECOG performance status: 0-1 8. Adequate organ function as defined by the following criteria: - White blood cells (WBC) = 4.0 x109/L - Platelet count = 100 x109/L - Hemoglobin =9 g/dl - Creatinine = 2 x ULN - Serum aspartate transaminase (AST; serum glutamic oxaloacetic transaminase [SGOT]) and serum alanine transaminase (ALT; serum glutamic pyruvic transaminase [SGPT]) = 2.5 x upper limit of normality (ULN) - Total serum bilirubin =1.5 x ULN. Exclusion Criteria: 1. Previous surgical/endoscopic treatments for prostatic disease 2. Herbal and non-herbal products that in the opinion of the investigator may decrease PSA levels 3. cM1 disease 4. Any contraindication for PET or MR investigations 5. History of seizure or condition that may pre-dispose to seizure (e.g., prior stroke within 1 year prior to randomization, brain arteriovenous malformation, Schwannoma, meningioma, or other benign CNS or meningeal disease which may require treatment with surgery or radiation therapy) 6. Medications known to lower the seizure threshold 7. History of: - Any prior malignancy (other than adequately treated basal cell or squamous cell skin cancer, superficial bladder cancer currently in complete remission) within 5 years prior to randomization - Severe/unstable angina, myocardial infarction, symptomatic congestive heart failure, arterial or venous thromboembolic events (e.g., pulmonary embolism, cerebrovascular accident including transient ischemic attacks), or clinically significant ventricular arrhythmias within 6 months prior to randomization - Uncontrolled hypertension (systolic blood pressure =160 mmHg or diastolic BP =100 mmHg). Patients with a history of uncontrolled hypertension are allowed provided blood pressure is controlled by anti-hypertensive treatment. - Gastrointestinal disorder affecting absorption 8. Any other condition that, in the opinion of the Investigator, would impair the patient's ability to comply with study procedures.

Study Design


Intervention

Drug:
ARN-509
240mg/day (4x60mg tablets, Oral administration: OS)
Degarelix
1st injection: 120mg Subcutaneous administration (SC) x2, 2nd-3rd SC injection 80mg monthly
Other:
Placebo
4 tablets, per OS

Locations

Country Name City State
Belgium University Hospitals Leuven Leuven Vlaams-brabant

Sponsors (1)

Lead Sponsor Collaborator
Universitaire Ziekenhuizen Leuven

Country where clinical trial is conducted

Belgium, 

Outcome

Type Measure Description Time frame Safety issue
Primary Minimal Residual Disease (MRD) Proportions of MRD between arms. MRD: tumor volume = 0.25 cm3 After 12 weeks of neoadjuvant therapy + RP + PLND
Secondary Difference in proportions of pathological downstage Any decrease in T stage from clinical to pathological stage After 12 weeks of neoadjuvant therapy + RP + PLND
Secondary Complete pathological response rates Difference in proportions of complete pathological response (no evidence of tumour in the postoperative specimen) between arms. After 12 weeks of neoadjuvant therapy + RP + PLND
Secondary Difference in proportions of patients with pN1 disease. Difference in proportions of lymph node invasion between arms After 12 weeks of neoadjuvant therapy + RP + PLND
Secondary Proteins expression in prostatic tumour TMA's (tissue microarrays) Intensity of immunoreactivity and percentage of immunoreactive cells for, selected markers between arms. The TMA's will be produced from the formalin-fixed paraffin-embedded (FFPE) specimen of the RP. After 12 weeks of neoadjuvant therapy + RP + PLND
Secondary Transcriptome analysis by microarray expression platform To assess differences in the transcriptome in tumour tissue on formalin-fixed paraffin-embedded (FFPE) specimens: clinical-grade high-density oligonucleotide microarray expression platform and cloud-based informatics pipeline to interrogate 1.4M probe sets representing all known ~46K genes and non-coding RNAs. At baseline and after 12 weeks of neoadjuvant therapy + RP + PLND
Secondary Pathway profiling and Gene Set Enrichment Analyses To assess differences in the transcriptome in tumour tissue on formalin-fixed paraffin-embedded (FFPE) specimens. Pathway profiling and Gene Set Enrichment Analyses will also be used to generate pathway scores for the 'androgen receptor signaling pathway'; determination of pathway scores for the DNA damage checkpoints and the different DNA repair pathways. At baseline and after 12 weeks of neoadjuvant therapy + RP + PLND
Secondary Genomic subtyping by exome-sequencing Genomic subtyping (e.g., ERG, SPINK1, SPOP, FOXA1, PTEN, circulating nucleic acids (CNA) data...) will be performed based on exome-sequencing data. The exome and CNA data will be linked with the transcriptome data on androgen regulation and DNA repair pathways. At baseline and after 12 weeks of neoadjuvant therapy + RP + PLND
Secondary PSA kinetics Changes of PSA during time and comparison of PSA values and changes between arms. Up to 40 months
Secondary Testosterone kinetics Comparison of total and free serum testosterone and testosterone change between arms Up to 40 months
Secondary PSA nadir </=0.3ng/ml after neoadjuvant treatment Differences in proportions of PSA nadir PSA nadir after neoadjuvant therapy and before external beam radiotherapy (EBRT) is an important biomarker of hormonal response and an independent prognostic factor of prostate cancer survival. After 12 weeks of neoadjuvant therapy before RP + PLND
Secondary Peri-operative features Differences in peri-operative features (operative time, blood loss, grade of surgical difficulty...) will be collected to evaluate the possible effect of treatment on surgical intervention. up to (about) 5 hours
Secondary Differences in proportions of surgical complications between arms Clavien-Dindo classification will be implemented to assess differences in surgical complications between the two arms. Up to 6 weeks post RP + PLND
Secondary Continence Assessment of continence rates through validated preoperative and postoperative questionnaire (ICIQ) Up to 40 months
Secondary Quality of life Assessment of Quality of life through validated preoperative and postoperative questionnaire (EORTC QLQ-C30) Up to 40 months
Secondary Erection state Assessment of erection state through validated preoperative and postoperative questionnaire (IEEF5) Up to 40 months
Secondary Survival Three years biochemical recurrence free survival Up to 36 months
Secondary Standardized Uptake Value (SUV) on pelvic [68]Ga PSMA PET/MR per arm Standardized Uptake Value (SUV) change (delta) per arm comparing SUV values before and after treatment At baseline and after 12 weeks of neoadjuvant therapy + RP + PLND
Secondary Standardized Uptake Value (SUV) on pelvic [68]Ga PSMA PET/MR between arms SUV delta between the two arms. After 12 weeks of neoadjuvant therapy + RP + PLND
Secondary Standardized Uptake Value (SUV) on pelvic [68]Ga PSMA PET/MR and tumour volume Correlation between SUV values and the tumour volume (TV) in the RP correspondent volume of interest (VOI) at definitive pathology After 12 weeks of neoadjuvant therapy + RP + PLND
Secondary Standardized Uptake Value (SUV) on prostate [68]Ga PSMA PET/MR and Immunohistochemistry Correlation between SUV values and PSMA expression at Immunohistochemistry After 12 weeks of neoadjuvant therapy + RP + PLND
Secondary Magnetic resonance (MR) and tumor volume (TV) per arm Change of magnetic resonance (MR) tumor volume (TV): Tumor volume (TV) change (delta) per arm comparing TV values before and after treatment At baseline and after12 weeks of neoadjuvant therapy + RP + PLND
Secondary Magnetic resonance (MR) and tumor volume (TV) between arms Change of magnetic resonance (MR) tumor volume (TV):TV deltas between the two arms. At baseline and after12 weeks of neoadjuvant therapy + RP + PLND
Secondary PI-RADS between arms at MR Proportion of PI-RADS between arms After 12 weeks of neoadjuvant therapy + RP + PLND
Secondary PI-RADS score and Gleason score Correlation between PI-RADS score and pathology Gleason score After 12 weeks of neoadjuvant therapy + RP + PLND
Secondary Down-staging at imaging Proportion of down-staging At baseline and after 12 weeks of neoadjuvant therapy + RP + PLND
Secondary Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] Frequencies of adverse events (AE), severe adverse events (SAE) and Suspected Unexpected Serious Adverse Reaction (SUSAR) From patient inclusion until RP + PLND
See also
  Status Clinical Trial Phase
Recruiting NCT05613023 - A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT Phase 3
Recruiting NCT05540392 - An Acupuncture Study for Prostate Cancer Survivors With Urinary Issues Phase 1/Phase 2
Recruiting NCT05156424 - A Comparison of Aerobic and Resistance Exercise to Counteract Treatment Side Effects in Men With Prostate Cancer Phase 1/Phase 2
Completed NCT03177759 - Living With Prostate Cancer (LPC)
Completed NCT01331083 - A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer Phase 2
Recruiting NCT05540782 - A Study of Cognitive Health in Survivors of Prostate Cancer
Active, not recruiting NCT04742361 - Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer Phase 3
Completed NCT04400656 - PROState Pathway Embedded Comparative Trial
Completed NCT02282644 - Individual Phenotype Analysis in Patients With Castration-Resistant Prostate Cancer With CellSearch® and Flow Cytometry N/A
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT06305832 - Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer Phase 2
Recruiting NCT05761093 - Patient and Physician Benefit/ Risk Preferences for Treatment of mPC in Hong Kong: a Discrete Choice Experiment
Completed NCT04838626 - Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection Phase 2/Phase 3
Recruiting NCT03101176 - Multiparametric Ultrasound Imaging in Prostate Cancer N/A
Completed NCT03290417 - Correlative Analysis of the Genomics of Vitamin D and Omega-3 Fatty Acid Intake in Prostate Cancer N/A
Completed NCT00341939 - Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
Completed NCT01497925 - Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer Phase 1
Recruiting NCT03679819 - Single-center Trial for the Validation of High-resolution Transrectal Ultrasound (Exact Imaging Scanner ExactVu) for the Detection of Prostate Cancer
Completed NCT03554317 - COMbination of Bipolar Androgen Therapy and Nivolumab Phase 2
Completed NCT03271502 - Effect of Anesthesia on Optic Nerve Sheath Diameter in Patients Undergoing Robot-assisted Laparoscopic Prostatectomy N/A